{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:36Z","timestamp":1777934256371,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>Immune therapy with checkpoint inhibitors has revolutionized the management of metastatic melanoma. Ipilimumab, nivolumab, and pembrolizumab are all FDA-approved immune checkpoint inhibitors to treat metastatic melanoma. Responses to immune checkpoint inhibitors are usually delayed. An interim progression on restaging computed tomography scans \u201cpseudo-progression\u201d may be observed before response to treatment occur. In this case, we report a significant interim progression of metastatic mucosal melanoma before meaningful responses to immunotherapy occurred. The patient developed significant immune therapy-related colitis and new onset vitiligo. Further restaging computed tomography scans showed sustained tumor response despite stopping the immune therapy.<\/jats:p>","DOI":"10.1177\/1078155215627503","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T20:43:47Z","timestamp":1453754627000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better"],"prefix":"10.1177","volume":"23","author":[{"given":"Shebli","family":"Atrash","sequence":"first","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Makhoul","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason S","family":"Mizell","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hutchins","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fade","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"key":"bibr1-1078155215627503","first-page":"154","volume":"26","author":"McCarthy EF","year":"2006","journal-title":"Iowa Orthop J"},{"key":"bibr2-1078155215627503","first-page":"3","volume":"105","author":"Coley WB","year":"1893","journal-title":"Clin Orthop Relat Res"},{"key":"bibr3-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"bibr4-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"bibr5-1078155215627503","unstructured":"Guha M. Immune checkpoint inhibitors bring new hope to cancer patients: feature."},{"key":"bibr6-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"bibr8-1078155215627503","unstructured":"Dummer R, Hamid O, O\u2019Day SJ, et\u00a0al. Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. In:\n                      The perspectives in melanoma XIV\n                      , Amesterdam, the Netherlands, 2010."},{"key":"bibr9-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0607"},{"key":"bibr10-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32835fb524"},{"key":"bibr11-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014528152"},{"key":"bibr12-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969"},{"key":"bibr13-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756"},{"key":"bibr14-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-S3-P103"},{"key":"bibr15-1078155215627503","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3971"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215627503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215627503","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215627503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:38Z","timestamp":1777688198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215627503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1177\/1078155215627503"],"URL":"https:\/\/doi.org\/10.1177\/1078155215627503","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,8]]}}}